Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight: PIPEing Hot Returns?

This article was originally published in The Pink Sheet Daily

Executive Summary

Novelos Therapeutics and Purdue Pharma's private placement agreement is among notable biotech financings from the past few weeks.

You may also be interested in...

Algeta Recruits Bayer To Deliver Prostate Cancer Drug Alpharadin To Market

Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.

Allos' Folotyn and Gloucster's Istodax: Exceptions That Prove The Rule?

ODAC continues to emphasize the importance of randomized controlled trials while supporting approval for two t-cell lymphoma drugs that conducted only singe-arm studies.

For a Look at IPO Future, Follow the Follow-On?

Three recent IPOs have stoked hopes that a broader IPO market may emerge. The market for follow-on public offerings though says more about a potential IPO resurgence than these recent debuts.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts